期刊文献+

哌罗匹隆与舒必利治疗以阴性症状为主的精神分裂症患者的对照研究 被引量:1

Comparative study of perospirone and sulpiride in treatment of schizophrenia characterized by negative symptoms
原文传递
导出
摘要 目的探讨哌罗匹隆与舒必利治疗以阴性症状为主的精神分裂症患者的疗效和安全性。方法将80例以阴性症状为主的精神分裂症患者随机分为实验组和对照组,各40例,分别口服哌罗匹隆、舒必利治疗,观察12周。并于治疗前、治疗4周、8周、12周末用阴性症状量表(SANS)和临床总体印象量表(CGI)评定临床疗效,用副反应量表评定不良反应。结果实验组显效率为72.5%,总有效率为92.5%;对照组显效率为70%,总有效率为90%,两组间比较差异无统计学意义(P>0.05);实验组不良反应的发生率显著低于对照组(P<0.01)。结论哌罗匹隆治疗以阴性症状为主的精神分裂症患者的疗效与舒必利相当,但哌罗匹隆的安全性更高。 Objective To compare the efficacy and safety of perospirone and sulpiride in the treatment of schizophrenia characterized by negative symptoms. Methods Totally 80 patients with negative symptoms of schizophrenia were ran- domly divided into experimental group and control group,40 cases in each,they respectively took orally perospirone and sulpiride for 8 weeks. And before treatment, treatment for 4 weeks,8 weeks, 12 weeks with negative symptom scale (SANS) and Clinical Global Impression Scale(CGI) assessment of clinical efficacy, side effects and side effects were e- valuated. Results The expeximental group was 72. 5% ,the total effective rate was 92. 5% ,the control group was 70%, the total effective rate was 90% ,There is no significant difference between the two groups( P 〉 0. 05 ) ;The incidence of adverse reaction in experimental group was significantly lower than that of the control group( P 〈 0. 01 ). Conclusion Perospirone has an evident effect equivalent to sulpiride in the treatment of schizophrenia characterized by negative symptoms, but the former has higher safe.
出处 《医药论坛杂志》 2014年第12期13-14,18,共3页 Journal of Medical Forum
关键词 哌罗匹隆 舒必利 阴性症状 精神分裂症 Perospirone Sulpiride Negative symptoms Schizophrenia
  • 相关文献

参考文献6

二级参考文献28

  • 1王来海,贾艳,黄素培.艾司西酞普兰[J].中国新药杂志,2005,14(6):790-792. 被引量:16
  • 2房茂胜,李乐华,翟金国,叶萌.新型抗精神病药:哌罗匹隆[J].中国新药与临床杂志,2006,25(7):548-551. 被引量:32
  • 3蔡文治,杨成龙,许海锋,夏伟君,张吕济.利培酮合并舍曲林治疗精神分裂症阴性症状的研究[J].上海精神医学,2006,18(6):349-351. 被引量:26
  • 4涂继莹,左笑丛,李焕德.非典型抗精神病药——哌罗匹隆[J].中国临床药理学杂志,2007,23(2):157-160. 被引量:25
  • 5中国医药数字图书馆,www.pharmaell.com,多巴胺D2/5HT2拮抗剂精神病药,哌罗匹隆.
  • 6Masui T, HonmaH, kondo C, et al. Perospimne therapy in elelerly patien - ts with schizophrenia Seishin Shinkeigaku Zasshi - Psycluatria. NeurdJpn. 2003 ;105:1247 - 1253.
  • 7Yoshino T,Nisijima K,Shioda k,et al. Perospirone,a novel a- typical antipsychotic drug, potentiates fluoxetine-indueed in- creases in dopmnine levels via multireceptor actions in the rat medial prefrontal cortex[J]. Neuroscienee Letters, 2004, 364 (1):16-21.
  • 8Masui T, Honma H, Kondo C, et al. Perospirone therapy in elderly patients with schizophrenia[J]. Seishin Shinkeigaku Zasshi, 2003,105 (10) : 1247-1253.
  • 9Yasui-Furukori N, Furukori H, Nakagami T, et al. Steady-state pharrnaeokineties of a new antipsyehotic agent perospirnoe and its active metabolite, and its relationship with prolaetin re- sponse[J]. Ther Drug Monit,2004,26(4):361-365.
  • 10Kitamura A, Mizuno Y,Natsui K,et al. Characterization of hu- man cytochrome P450 enzymes involved in the in vitro me- tabolismof perospirone[J]. Biopharm Drug Dispos, 2005, 26 (2):59-65.

共引文献39

同被引文献13

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部